AbbVie Inc. (ABBV)
NYSE: ABBV · IEX Real-Time Price · USD
165.96
-4.41 (-2.59%)
At close: Jul 2, 2024, 4:00 PM
166.14
+0.18 (0.11%)
After-hours: Jul 2, 2024, 7:59 PM EDT
AbbVie Employees
AbbVie had 50,000 employees as of January 31, 2024. The number of employees did not change compared to the previous year.
Employees
50,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,088,060
Profits / Employee
$119,860
Market Cap
293.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Jan 31, 2024 | 50,000 | 0 | - |
Jan 31, 2023 | 50,000 | 0 | - |
Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
Jan 31, 2020 | 30,000 | 0 | - |
Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ABBV News
- 16 hours ago - AbbVie to Host Second-Quarter 2024 Earnings Conference Call - PRNewsWire
- 1 day ago - Robert A. Michael Assumes Role as AbbVie Chief Executive Officer - PRNewsWire
- 4 days ago - AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma - PRNewsWire
- 5 days ago - AbbVie Acquires Celsius Therapeutics - PRNewsWire
- 5 days ago - Introducing Allē Payment Plans, Powered by Cherry - PRNewsWire
- 6 days ago - U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma - PRNewsWire
- 7 days ago - US FDA declines to approve AbbVie's Parkinson's disease therapy - Reuters
- 7 days ago - AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) - PRNewsWire